Sullivan Baby Doe Awarded Default Judgment Against Endo Pharmaceuticals
News provided by
Share this article
Share this article
KINGSPORT, Tenn., April 7, 2021 /PRNewswire/ In a ruling filed in Sullivan County Circuit Court on April 6, 2021, Chancellor E.G. Moody granted a default judgment against Endo Health Solutions, Inc. and Endo Pharmaceuticals, Inc. in the case of Staubus vs. Purdue, widely recognized as the Sullivan Baby Doe suit. Baby Doe is represented by the firm of Branstetter, Stranch & Jennings of Nashville, Tennessee.
The judgment details a dozen false statements Endo s attorneys made to the court, describes a coordinated strategy between Endo and its counsel to…interfere with the administration of justice, and holds the companies liable for damages sought, an amount that totals $2.4 billion.
Judge In Sullivan Baby Doe Case Allows $2.4 Billion Judgment Trial Wednesday, April 7, 2021
In a ruling filed in Sullivan County Circuit Court on Tuesday, Chancellor E.G. Moody granted a default judgment against Endo Health Solutions, Inc. and Endo Pharmaceuticals, Inc. in the case of Staubus vs. Purdue, widely recognized as the Sullivan Baby Doe suit.
The judgment details a dozen false statements Endo’s attorneys made to the court, describes a “coordinated strategy between Endo and its counsel to…interfere with the administration of justice,” and holds the companies liable for damages sought, an amount that totals $2.4 billion, prosecutors said.
Health
your username
February 9, 2021 A class-action complaint was filed Friday in the Middle District of Tennessee against Medicare Advantage insurer Clover Health Investments and three Clover officials over allegedly representing their company in ways that inflated its common stock share price, only to deflate after a report claimed to reveal that such representations were misleading.
After a merger was completed Jan. 7 between Clover and Social Capital Hedosophia Holdings Corp. III (SCH), which is traded on the New York Stock Exchange under ticker symbol “IPOC,” Clover became a publicly traded company under “CLOV.” The IPOC/CLOV common stock traded at up to $17.45 per share during the class period (beginning Oct. 6, 2020, when the companies announced their merger), according to the complaint.
The Tennessee Supreme Court ruled last week that defendants in the âSullivan Baby Doeâ and similar lawsuits can be sued for damages by infants harmed by their mothersâ use of opioids under the Tennessee Drug Dealer Liability Act.
The court also ruled that district attorneys general who individually sued the pharmaceutical opioid companies on behalf of their districts did not have standing to sue under the DDLA.
Prescription opioid manufacturers Endo Health Solutions Inc., Endo Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc. remain as defendants in lawsuits filed by Tennessee district attorneys general.
The âSullivan Baby Doeâ lawsuit, named for a baby born addicted to opiates in 2015 at Holston Valley Medical Center, was filed in June 2017. It spurred similar lawsuits filed by district attorneys general in other Tennessee counties, including a 2017 civil action filed by seven district attorneys general representing Campbell, Cocke and other counti